Index Entries

Peter I. Parry, Astrid Lefringhausen, Conny Turni, Christopher J. Neil, Robyn Cosford, Nicholas J. Hudson, and Julian Gillespie
August 17, 2023
Biomedicines
University of Queensland (Australia)

"Introduction: In this narrative review, we examine the solid evidence for a counter-narrative to the ‘safe and effective’ message that has accompanied the novel product COVID-19 vaccines, which were developed at ‘warp speed’ with great hope to end the pandemic. This evidence has accumulated and dampened the original optimism. The implications for the recognition of vaccine-related diagnoses and the need for therapeutics are significant for all health practitioners and many research scientists to consider.

Key problem areas appear to be (1) the toxicity of the spike protein—both from the virus and also when produced by gene codes in the novel COVID-19 mRNA and adenovectorDNA vaccines, hence the novel term ‘spikeopathy’; (2) inflammatory properties of certain lipid-nanoparticles used to ferry mRNA; (3) N1-methylpseudouridine in the synthetic mRNA that causes long-lasting action; (4) widespread biodistribution of the mRNA and DNA codes via the lipid-nanoparticle and the viral-vector carrier matrices, respectively, and (5) the problem of human cells producing a foreign protein in our ribosomes that can engender autoimmunity...

The aim of this narrative review is to present a comprehensive account of the pathogenicity of the antigen, the biodistribution of the gene codes for the antigen throughout the body, their modified long-lasting nature particularly with the mRNA vaccines, and literature and data that show the adverse events that would be expected from such biodistribution and cellular production of a foreign antigen. The review presents a case of premature translation of experimental gene therapy technology to mass public vaccination and ethical and regulatory issues that need scrutiny and reform before the next pandemic...

9. Conclusions

In this narrative review, we have established the role of the SARS-CoV-2 spike protein, especially the S1 subunit, as pathogenic. It is also now apparent that widely biodistributed spike proteins, produced by mRNA and adenovectorDNA gene codes, induce a wide variety of diseases. The underlying pathophysiological and biochemical mechanisms are being elucidated. The lipid-nanoparticle carriers for the mRNA and Novavax vaccines have pathological pro-inflammatory properties as well. The whole premise of gene-based vaccines producing foreign antigens in human tissues is fraught with risks for autoimmune and inflammatory disorders, especially when the distribution is not highly localised.

The clinical implications that follow are that clinicians in all fields of Medicine need to be mindful of the varied possible presentations of COVID-19 vaccine-related illness, both acute and chronic, and the worsening of pre-existing conditions. We also advocate for the suspension of gene-based COVID-19 vaccines and lipid-nanoparticle carrier matrices, and other vaccines based on mRNA or viral-vectorDNA technology. A safer course is to use vaccines with well-tested recombinant protein, attenuated or inactivated virus technologies, of which there are now many for vaccinating against SARS-CoV-2."

document
adverse events,COVID-19,credentialed opposition,gene therapy,immunodeficiency and immunopathological disorders,lipid nanoparticles,mRNA,SARS-CoV-2 spike protein,vaccine biodistribution,vaccines